Liu Can-Tong, Hong Chao-Qun, Huang Xu-Chun, Li En-Min, Xu Yi-Wei, Peng Yu-Hui
Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Precision Medicine Research Center, Shantou University Medical College, Shantou, Guangdong, China.
J Cancer. 2020 Apr 27;11(15):4332-4342. doi: 10.7150/jca.44545. eCollection 2020.
Esophagogastric junction cancer poses a great threat to human beings both in western countries and East Asia, especially in China and Japan, and its incidence has increased during recent decades. The 5-year survival rate of esophagogastric junction cancer is quite poor compared with that of other gastric cancer sites. Until now, the traditional TNM staging system has been widely used in clinical practice for prognosis. However, the TNM system is based on pathology after surgical resection or radiology using CT and MRI, not on blood markers. Evidently, some research has been reported concentrated on the prognostic value of blood-based markers with the character of non-invasive and non-radioactive in EJA. Hematologic, biochemical and coagulation parameters could be obtained from clinical data and utilized to analyze their prognostic values. Tumor-associated antigens, microRNAs and circulating tumor cells have also been reported in EJC prognosis. In this article, we review research focused on blood-based markers to evaluate their prognostic value in esophagogastric junction cancer, especially its main subtype adenocarcinoma.
食管胃交界癌在西方国家和东亚地区，尤其是在中国和日本，对人类构成了巨大威胁，且其发病率在最近几十年有所上升。与其他胃癌部位相比，食管胃交界癌的5年生存率相当低。到目前为止，传统的TNM分期系统在临床实践中被广泛用于预后评估。然而，TNM系统是基于手术切除后的病理或使用CT和MRI的放射学检查，而非基于血液标志物。显然，已有一些研究报道集中于具有非侵入性和非放射性特点的血液标志物在食管胃交界癌中的预后价值。血液学、生化和凝血参数可从临床数据中获取，并用于分析其预后价值。肿瘤相关抗原、微小RNA和循环肿瘤细胞在食管胃交界癌预后方面也有报道。在本文中，我们综述了聚焦于血液标志物以评估其在食管胃交界癌，尤其是其主要亚型腺癌中的预后价值的研究。
